<DOC>
	<DOCNO>NCT01528930</DOCNO>
	<brief_summary>The incidence chronic pulmonary disease cause nontuberculous mycobacteria ( NTM ) human immunodeficiency virus ( HIV ) -negative patient increase worldwide . In Korea , common etiologic pathogen disease Mycobacterium avium complex ( MAC ) Mycobacterium abscessus . Treating NTM lung diseases extremely difficult may require multiple drug . Amikacin effective antibiotic NTM infection . However , intravenous amikacin treatment limited systemic route administration lot adverse event . Amikacin inhalation treatment could overcome limitation also could effective treatment NTM pulmonary disease due maintain high lung concentration . The purpose study determine whether amikacin inhalation treatment effective patient MAC infection experience treatment failure standard treatment 6 month M. abscessus infection .</brief_summary>
	<brief_title>Inhaled Amikacin Treatment Nontuberculous Mycobacterial Lung Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Amikacin</mesh_term>
	<criteria>1 . Diagnosis NTM lung lung disease accordance 2007 ATS/IDSA criterion . 2 . MAC lung disease persistent sputum culture positive 6 month standard treatment 3 . M. abscessus lung disease persistent sputum culture positive 6 month standard treatment 4 . New case M. abscessus pulmonary disease completion initial 4 week intravenous antibiotic treatment 1 . Subjects negative sputum culture start study 2 . Forced expiratory volume 1 second ( FEV1 ) &lt; 30 % predict screening . 3 . Positive HIV test . 4 . Subjects chronic renal insufficient state ( serum creatinine level 2.0 mg/dL ) 5 . Subjects decrease liver function ( serum total bilirubin level 2 mg/dL AST ALT 1.5 time upper normal limit ) 6 . Active malignancy require chemotherapy radiation therapy within one year prior screen . 7 . Subjects history allergy amikacin . 8 . Subjects pregnant state woman childbearing age appropriate contraception .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Lung Diseases</keyword>
	<keyword>Anti-Infective Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Amikacin</keyword>
</DOC>